Associated Papers
Crovalimab Rescue Therapy in a Case With Genetic Complement Mediated Thrombotic Microangiopathy.
Aigner C et al.
Kidney Medicine, 2026
From uterine atony to aHUS: A case of postpartum thrombotic microangiopathy.
Blanco Flores JM et al.
Revista Espanola De Anestesiologia Y Reanimacion, 2026
Evaluation of the impact of two C5 genetic variants on C5-eculizumab complex stability at the molecular level.
Peixoto VP et al.
Journal of Biomolecular Structure & Dynamics, 2025
Immunological Targets in Generalized Myasthenia Gravis Treatment: Where Are We Going Now?
Rossini E et al.
Brain Sciences, 2025
Eculizumab for adult patients with atypical haemolytic-uraemic syndrome: full dataset analysis of Japanese post-marketing surveillance.
Maruyama S et al.
Journal of Nephrology, 2024
Paroxysmal Nocturnal Hemoglobinuria, Pathophysiology, Diagnostics, and Treatment.
Panse JP et al.
Transfusion Medicine and Hemotherapy : Offizielles Organ Der Deutschen Gesellschaft Fur Transfusionsmedizin Und Immunhamatologie, 2024
Phase 3 randomized COMMODORE 1 trial: Crovalimab versus eculizumab in complement inhibitor-experienced patients with paroxysmal nocturnal hemoglobinuria.
Scheinberg P et al.
American Journal of Hematology, 2024
The efficacy and safety of eculizumab in patients and the role of C5 polymorphisms.
Bouwman HB et al.
Drug Discovery Today, 2024
Characterization of the bispecific VHH antibody gefurulimab (ALXN1720) targeting complement component 5, and designed for low volume subcutaneous administration.
Jindal S et al.
Molecular Immunology, 2024
Crovalimab treatment in patients with paroxysmal nocturnal haemoglobinuria: Long-term results from the phase I/II COMPOSER trial.
Röth A et al.
European Journal of Haematology, 2023
Inhibition of cleavage of human complement component C5 and the R885H C5 variant by two distinct high affinity anti-C5 nanobodies.
Struijf EM et al.
The Journal of Biological Chemistry, 2023
Eculizumab for paediatric patients with atypical haemolytic uraemic syndrome: full dataset analysis of post-marketing surveillance in Japan.
Ito S et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association, 2023
Zilucoplan, a macrocyclic peptide inhibitor of human complement component 5, uses a dual mode of action to prevent terminal complement pathway activation.
Tang GQ et al.
Frontiers in Immunology, 2023
Tesidolumab (LFG316) for treatment of C5-variant patients with paroxysmal nocturnal hemoglobinuria.
Nishimura JI et al.
Haematologica, 2022
Tackling COVID-19 infection through complement-targeted immunotherapy.
Jodele S et al.
British Journal of Pharmacology, 2021
Suitable indications of eculizumab for patients with refractory generalized myasthenia gravis.
Oyama M et al.
Therapeutic Advances in Neurological Disorders, 2020
Clinical promise of next-generation complement therapeutics.
Mastellos DC et al.
Nature Reviews. Drug Discovery, 2019
Pharmacology, Pharmacokinetics and Pharmacodynamics of Eculizumab, and Possibilities for an Individualized Approach to Eculizumab.
Wijnsma KL et al.
Clinical Pharmacokinetics, 2019
A small-molecule inhibitor of C5 complement protein.
Jendza K et al.
Nature Chemical Biology, 2019
Three months interval therapy of Eculizumab in a patient with atypical hemolytic uremic syndrome with hybrid CFHR1/CFH gene.
Alobaidi S et al.
Cen Case Reports, 2019
The rational design of affinity-attenuated OmCI for the purification of complement C5.
Macpherson A et al.
The Journal of Biological Chemistry, 2018
Ten Years of Clinical Experience With Eculizumab in Patients With Paroxysmal Nocturnal Hemoglobinuria.
Sicre de Fontbrune F et al.
Seminars in Hematology, 2018
Diseases of complement dysregulation-an overview.
Wong EKS et al.
Seminars in Immunopathology, 2018
Long lasting neutralization of C5 by SKY59, a novel recycling antibody, is a potential therapy for complement-mediated diseases.
Fukuzawa T et al.
Scientific Reports, 2017
Small-molecule factor D inhibitors selectively block the alternative pathway of complement in paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome.
Yuan X et al.
Haematologica, 2017
Extravascular hemolysis and complement consumption in Paroxysmal Nocturnal Hemoglobinuria patients undergoing eculizumab treatment.
Subías Hidalgo M et al.
Immunobiology, 2017
PASylated Coversin, a C5-Specific Complement Inhibitor with Extended Pharmacokinetics, Shows Enhanced Anti-Hemolytic Activity in Vitro.
Kuhn N et al.
Bioconjugate Chemistry, 2016
Stratification of responders towards eculizumab using a structural epitope mapping strategy.
Volk AL et al.
Scientific Reports, 2016
Genetic variants of C5 and polymorphisms of C3 in Chinese patients with paroxysmal nocturnal hemoglobinuria.
Du Y et al.
International Journal of Laboratory Hematology, 2016
Patient stratification and therapy in atypical haemolytic uraemic syndrome (aHUS).
Wong E et al.
Immunobiology, 2016
[Genetic variants in C5 and poor response to eculizumab].
Nishimura J
[rinsho Ketsueki] the Japanese Journal of Clinical Hematology, 2015
Anticomplement C5 therapy with eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome.
Wong EK et al.
Translational Research : the Journal of Laboratory and Clinical Medicine, 2015
[The C5 gene polymorphism in patients with PNH].
Nishimura J et al.
[rinsho Ketsueki] the Japanese Journal of Clinical Hematology, 2015
Genetic variants in C5 and poor response to eculizumab.
Nishimura J et al.
The New England Journal of Medicine, 2014
Complement therapy in atypical haemolytic uraemic syndrome (aHUS).
Wong EK et al.
Molecular Immunology, 2013